awmsg logo



certolizumab pegol (Cimzia®)


Reference No. 1713

Publication date:
31/10/2014


Appraisal information

certolizumab pegol (Cimzia®) 200 mg solution for injection


Company: UCB Pharma Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 10/09/2014
AWMSG meeting date: 08/10/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 3214
Ministerial ratification: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Certolizumab pegol (Cimzia®), in combination with methotrexate, is recommended as an option for use within NHS Wales for the treatment of active psoriatic arthritis in adults when the response to previous disease modifying antirheumatic drug therapy has been inadequate. Certolizumab pegol can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download